Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The HER2+ Gastric Cancer Market is set to witness immense growth during the forecast period 2022-2028. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufacturers/players/vendors analysis, segments & sub-segments, and forecast. The report also focuses on market drivers, challenges (current and future), revenue growth, future roadmap, standardization, deployment models, and forecast analysis.
Overview:
Gastric cancer occurs when cancer cells grow inside the stomach's lining. Certain factors increase the risk of developing the disease, including smoking, obesity, and H. pylori infection. Certain inherited conditions are also associated with an increased risk of developing gastric cancer. During treatment, a biopsy will be performed to determine the exact type of gastric cancer. This test involves the removal of a sample of tissue or fluid, which is then sent to a pathologist for examination under a microscope. A biopsy will also determine if the tumor is HER2-positive. If it is, then a monoclonal antibody may be used to treat cancer. In the first stage of stomach cancer, there are no symptoms. Cancer may spread to nearby lymph nodes and distant organs. In stage two and stage three, cancer has already spread beyond the stomach lining. Fortunately, treatment options are available and gastric cancer can be cured in some cases. If you have symptoms of gastric cancer, your health care provider will be able to determine the best treatment options.
The global HER2+ gastric cancer market focuses on six regions, such as North America, Asia Pacific, South America, Europe, the Middle East, and Africa.
Drivers:
The increasing prevalence of gastric cancer is expected to fuel the growth of the global HER2+ gastric cancer market over the forecast period. For instance, according to The Lancet, in 2020, there were around 1.1 million gastric cancer cases in the world. In addition to surgery, treatment may include immunotherapy. Immunotherapy treatments will boost the immune system to attack cancer cells. Immunotherapy is often used for advanced and recurring cancers. In addition, patients may receive palliative care, which is a team approach aimed at improving the quality of life while undergoing treatment for cancer. The nurses and doctors working with patients may help with pain management, symptom relief, and additional support. Increasing technological advancements in cancer treatments are estimated to enhance the growth of the global HER2+ gastric cancer market.
Restraints:
Less awareness about HER2-positive gastric cancer is expected to hinder the growth of the global HER2+ gastric cancer market.
Regional Insights:
In regions, North America is expected to hold a major share of the global HER2+ gastric cancer market, owing to the increasing prevalence of gastric cancer in the region. For instance, according to the American Cancer Society, currently, there are around 26,380 newly diagnosed cases of stomach cancer in the United States. Moreover, the Asia Pacific is estimated to witness significant growth in the global HER2+ gastric cancer market owing to the increasing expansion of cancer care centers in the region.
Competitive Section:
Key players operating in the global HER2+ gastric cancer market include Eli Lilly and Company, OncXerna Therapeutics, Inc, Merus N.V., Eisai Inc, Merck Sharp & Dohme Corp., MacroGenics/Zai Lab, Seagen, Jiangsu HengRui Medicine, Shanghai Henlius Biotech, LintonPharm, Hutchison Medipharma, Bristol-Myers Squibb, Bayer, and AstraZeneca.
HER2+ Gastric Cancer Market Dynamics:
This market study estimates the market size in terms of both value (million USD) and volume (K Units). The HER2+ Gastric Cancer Market report analyses market trends based on historical data and the latest developments. It provides both qualitative and quantitative data on the elements that will shape the market's growth from 2022 to 2028. The market capacity and consumption potential of major companies are discussed in this research report. Furthermore, it concentrates on prominent regions (Latin America, Europe, Asia Pacific, Africa, and the Middle East). Also, the report evaluates COVID-19's impact on the HER2+ Gastric Cancer Market.
Companies profiled in the HER2+ Gastric Cancer Market report include:
- Roche
- AstraZeneca
- Astellas Pharma
- RemeGen
- Others
The report covers extensive competitive intelligence which includes the following data points:
⇨ Business Overview
⇨ Business Model
⇨ Financial Data
⇨ Financial – Existing
⇨ Financial – Funding
⇨ Product/Service Segment Analysis and specification
⇨ Recent Development and Company Strategy Analysis
⇨ SWOT Analysis
Segmentation by Type:
The type segment contributed the largest share to the HER2+ Gastric Cancer Market in 2021; this segment is projected to grow at the highest CAGR from 2022 to 2028.
- RC48
- Enhertu
- Zolbetuximab
- Herceptin
Segmentation by Application:
An end-use industry is projected to grow at the highest CAGR during the forecast period, due to rapid development in emerging economies North America, APAC, MEA, Europe, and ROW.
- Hospitals & Clinics
- Home Care Settings
- others
Key Benefits for Stakeholders:
- The study represents a quantitative analysis of the present HER2+ Gastric Cancer Market trends, estimations, and dynamics of the market size from 2022 to 2028 to determine the most promising opportunities.
- Porter's five forces study emphasizes the importance of buyers and suppliers in assisting stakeholders to make profitable business decisions and expand their supplier-buyer network.
- In-depth analysis, as well as market size and segmentation, help you identify current HER2+ Gastric Cancer Market opportunities.
- The largest countries in each region are mapped according to their revenue contribution to the market.
- The HER2+ Gastric Cancer Market research report gives a thorough analysis of the current status of the HER2+ Gastric Cancer Market's major players.
Reasons to Purchase HER2+ Gastric Cancer Market Report:
- Both current and future prospects for the HER2+ Gastric Cancer Market in developed and emerging markets.
- Analysis of various perspectives of the market with the help of Porter’s five forces analysis.
- During the forecast period, major regions are expected to see the most rapid increase.
- Identify the most recent advancements, HER2+ Gastric Cancer Market shares, and top market players' strategies.
Research Methodology:
To estimate and validate the size of the HER2+ Gastric Cancer Market and many other dependent submarkets in the overall market, both top-down and bottom-up methodologies are utilized. Key players in the market have been identified through secondary research and their market shares have been determined through primary and secondary research. Secondary sources and verified primary sources were used to determine all percentage share splits and breakdowns.
